Aptevo extends shareholder rights plan expiration to November 4, 2023

Aptevo Therapeutics Inc.

Amendment No. 2 to Rights Agreement extends Final Expiration Date to Nov 4, 2023.
Rights Agreement originally dated Nov 8, 2020, amended Nov 5, 2021, and now Nov 4, 2022.
Rights pertain to contingent purchase of one one-thousandth of Series A Junior Participating Preferred Stock.
Broadridge Corporate Issuer Solutions remains Rights Agent.
No changes to other terms or exercise price of rights.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.7

Aptevo Therapeutics Inc. amended "Rights Agreement" with Broadridge Corporate Issuer Solutions, Inc. valued at 1011 (effective 2022-11-04).

Action: amendment
Counterparty: Broadridge Corporate Issuer Solutions, Inc.
Value: 1011
Effective: 2022-11-04

Exact text from the filing

On November 4, 2022, Aptevo Therapeutics Inc. (the “Company”) entered into Amendment No. 2 (the “Amendment”) to the Rights Agreement, dated as of November 8, 2020, between the Company and Broadridge Corporate Issuer Solutions, Inc., as Rights Agent, as amended on November 5, 2021 (the “Rights Agreement”).

View on SEC.gov

Browse all material agreements →

Aptevo Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001564590-22-036769

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.